MedTrace Logo

Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients

NCT00846157 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 276

Last updated 2011-06-28

No results posted yet for this study

Summary

Primary objective:

* To compare the event free survival for 3years of R-CHOP plus Biocell Natural Killer Cell to R-CHOP therapy with DLBCL patients.

Conditions

  • Diffuse Large B-cell Lymphoma

Interventions

BIOLOGICAL

NKM injection

NKCell about 100mg IV for 6times in each chemotherapy period.

Sponsors & Collaborators

  • NKBio Co.Ltd.

    lead INDUSTRY

Principal Investigators

  • Seok-Goo Cho, MD,PhD · Catholic Hematopoietic Stem Cell Transplantation Center in The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2011-09-30
Completion
2014-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00846157 on ClinicalTrials.gov